Physician profile
Olga Badem
NPI 1295704963
$6,193.89
in general payments reported to CMS, 2019-2025
22 companies · $517 in 2025
The $517 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $719 · 2020: $695 · 2021: $763 · 2022: $727 · 2023: $1,350 · 2024: $1,423 · 2025: $517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,289 · Education: $1.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,288.73 |
| Education | $1.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,181.62 | 2021-2025 | Dovato, Rukobia, Cabenuva |
| Gilead Sciences, INC. | $1,066.66 | 2019-2025 | |
| Janssen Biotech, INC. | $834.05 | 2019-2023 | Symtuza |
| Abbvie INC. | $725.12 | 2020-2024 | Mavyret, Dalvance |
| Janssen Products, LP | $435.98 | 2019-2023 | Symtuza |
| Shionogi INC | $319.31 | 2021-2024 | Fetroja |
| Insmed, INC. | $266.98 | 2019-2025 | Arikayce |
| Janssen Pharmaceuticals, INC | $265.58 | 2019-2024 | Xarelto |
| Allergan, INC. | $200.15 | 2019-2020 | |
| Emd Serono, INC. | $187.06 | 2019-2024 | Serostim |
| Melinta Therapeutics, LLC | $173.53 | 2019-2024 | Orbactiv, Kimyrsa, Rezzayo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.28 | 2023-2025 | Jardiance |
| Shire North American Group INC | $73.74 | 2019 | |
| Exact Sciences Corporation | $62.39 | 2024 | Cologuard Collection Kit |
| Janssen Scientific Affairs, LLC | $55.11 | 2023 | Symtuza, Prezista |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Theratechnologies INC. | $52.05 | 2025 | Egrifta, Trogarzo |
| Merck Sharp & Dohme LLC | $39.42 | 2022-2025 | Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $38.69 | 2019-2022 | |
| Pfizer INC. | $29.57 | 2025 | |
| Brainsway USA INC | $23.64 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $23.22 | 2024 | Uzedy |
| Otsuka America Pharmaceutical, INC. | $19.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olga Badem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.